{"nctId":"NCT01916980","briefTitle":"Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Eczema/Dermatitis and Dermal Pruritus (MK-4117-202)","startDateStruct":{"date":"2013-08-27","type":"ACTUAL"},"conditions":["Eczema","Dermatitis","Dermal Pruritus"],"count":94,"armGroups":[{"label":"Desloratadine: Eczema/Dermatitis","type":"EXPERIMENTAL","interventionNames":["Drug: Desloratadine 5 mg"]},{"label":"Desloratadine: Dermal Puritus","type":"EXPERIMENTAL","interventionNames":["Drug: Desloratadine 5 mg"]}],"interventions":[{"name":"Desloratadine 5 mg","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Eczema/dermatitis (acute eczema, chronic eczema, contact dermatitis, atopic dermatitis, nummular eczema, seborrheic dermatitis, asteatotic eczema, neurodermatitis, etc. among eczema/dermatitis for which the observation of pruritus is appropriate)\n* Dermal pruritus (generalized dermal pruritus, localized dermal pruritus)\n\nExclusion Criteria:\n\n* Hypersensitivity to antihistamines or ingredients of a study drug","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Pruritus/Itch Score (Sum of Daytime and Nighttime Scores) Assessed by the Investigator at Week 2","description":"The Investigator assessed the severity of participant pruritus/itch during the daytime (0=Virtually no itching to 4=Cannot relax because of constant itching) and nighttime (0=Virtually no itching to 4=Cannot sleep because of itching). The sum of the daytime and nighttime pruritus/itch scores could range from 0 to 8, with a higher sum score indicating greater severity. The change from Baseline in the sum of the daytime and nighttime pruritus/itch scores at Week 2 clinic visit was calculated.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.63","spread":null},{"groupId":"OG001","value":"-2.17","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Experienced at Least One Adverse Event (AE)","description":"An AE is any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug or protocol-specified procedure, whether or not considered related to the study drug or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that is temporally associated with the use of the study drug is also an AE.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.8","spread":null},{"groupId":"OG001","value":"48.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Discontinued Study Drug Due to an AE","description":"An AE is any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug or protocol-specified procedure, whether or not considered related to the study drug or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that is temporally associated with the use of the study drug is also an AE.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.2","spread":null},{"groupId":"OG001","value":"6.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Pruritus/Itch Score (Sum of Daytime and Nighttime Scores) Assessed by the Investigator at Day 3, Week 1, Week 4, Week 6, Week 8 and Week 12","description":"The Investigator assessed the severity of participant pruritus/itch during the daytime (0=Virtually no itching to 4=Cannot relax because of constant itching) and nighttime (0=Virtually no itching to 4=Cannot sleep because of itching). The sum of the daytime and nighttime pruritus/itch scores could range from 0 to 8, with a higher sum score indicating greater severity. The changes from Baseline in the sum of the daytime and nighttime pruritus/itch scores at the Day 3, Week 1, Week 4, Week 6, Week 8 and Week 12 clinic visits were calculated.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.83","spread":null},{"groupId":"OG001","value":"-1.59","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.29","spread":null},{"groupId":"OG001","value":"-2.07","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.88","spread":null},{"groupId":"OG001","value":"-2.39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.33","spread":null},{"groupId":"OG001","value":"-2.48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.18","spread":null},{"groupId":"OG001","value":"-3.15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.51","spread":null},{"groupId":"OG001","value":"-3.47","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Moderate or Remarkable Improvement in the Global Improvement Rate of Pruritus/Itch Assessed by the Investigator at Day 3, Week 1, Week 2, Week 4, Week 6, Week 8 and Week 12","description":"The global improvement judgment criteria were used to assess overall improvement in pruritus/itch. The Investigator assessed the degree of severity of pruritus/itch based on 5 grades (1=Remarkably improved to 5=Aggravated) at Baseline and subsequent clinic visits. The percentages of participants who were remarkably improved (Grade 1=Pruritus/itch disappeared) or moderately improved (Grade 2=Pruritus/itch was greatly improved) at the Day 3, Week 1, Week 2, Week 4, Week 6, Week 8 and Week 12 clinic visits were calculated.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.9","spread":null},{"groupId":"OG001","value":"34.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.2","spread":null},{"groupId":"OG001","value":"51.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.8","spread":null},{"groupId":"OG001","value":"51.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.8","spread":null},{"groupId":"OG001","value":"62.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.0","spread":null},{"groupId":"OG001","value":"62.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.1","spread":null},{"groupId":"OG001","value":"62.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.2","spread":null},{"groupId":"OG001","value":"62.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Pruritus/Itch Visual Analog Scale (VAS) Score Recorded by Participants at Day 3, Week 1, Week 2, Week 4, Week 6, Week 8 and Week 12","description":"Participants assessed the degree of their pruritus using a 100-mm visual analog scale (VAS; 0mm=No itch, 100mm=Worst imaginable itch) at Baseline and subsequent clinic visits. Pruritus/itch VAS scores could range from 0 to 100, with a higher score indicating more severe pruritus/itching. The changes from Baseline in the VAS scores for pruritus/itch at the Day 3, Week 1, Week 2, Week 4, Week 6, Week 8 and Week 12 clinic visits were calculated.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.03","spread":null},{"groupId":"OG001","value":"-21.90","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.17","spread":null},{"groupId":"OG001","value":"-24.72","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.95","spread":null},{"groupId":"OG001","value":"-28.45","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-22.36","spread":null},{"groupId":"OG001","value":"-27.74","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-27.26","spread":null},{"groupId":"OG001","value":"-30.71","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-29.87","spread":null},{"groupId":"OG001","value":"-32.44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-33.02","spread":null},{"groupId":"OG001","value":"-38.74","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":65},"commonTop":["Nasopharyngitis","Somnolence","Seborrhoeic dermatitis"]}}}